Inflammatory anemia
Conditions
Interventions
The roxadustat treatment observation group:None
Sponsors
Beijing Chao-Yang Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age is 18 years or older. 2. The diagnostic process and indicators for inflammatory anemia comply with the relevant disease treatment guidelines. Diagnostic criteria for inflammatory anemia: (1) There is often a chronic disease, such as chronic infection, inflammation or tumor, etc. In addition, these chronic diseases combined with blood loss, hemolysis and drug-induced bone marrow suppression need to be excluded. (2) It is usually normocytic normochromic anemia, 30% to 50% is microcytic hypochromic anemia, and reticulocytes are normal. (3) Serum iron and total iron binding capacity are below normal, transferrin saturation is normal or slightly low (16% to 30%), serum ferritin is elevated, which is consistent with the manifestations of abnormal iron metabolism. Mainly includes patients with inflammatory anemia caused by autoimmune diseases and myelodysplastic syndrome (MDS). 3. ECOG score is 0-2. 4. The medical records are complete, and at least 8 weeks of pre-treatment and post-treatment hemoglobin data and other key indicators can be extracted.
Exclusion criteria
Exclusion criteria: 1.Patients who are currently using or have used immunosuppressive agents (such as hormones, MTX, etc.) within the past year, except when required for the primary disease. 2.Poorly controlled severe hypertension. 3.Untreated iron, folate, or vitamin B12 deficiency; hemolytic anemia; transfusion-dependent anemia. 4.The presence of severe cardiac, pulmonary, or hepatic insufficiency (e.g., NYHA Class III-IV heart failure, COPD GOLD 3-4, Child-Pugh Class B or C cirrhosis, etc.). 5.Patients with a documented diagnosis of VTE (including deep vein thrombosis of the lower extremities and pulmonary embolism) that was not resolved prior to the initiation of Roxadustat treatment. 6.Patients with extremely incomplete medical records that cannot be used for primary efficacy or safety analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 8-week Anemia Remission Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 8-week Hemoglobin Improvement Rate;Quality of Life (QOL) and ECOG Score Improvement; | — |
Countries
China
Contacts
Public ContactAijun Liu
Beijing Chao-Yang Hospital, Capital Medical University
Outcome results
None listed